Lupus erythematosus: Management of cutaneous manifestations during pregnancy

被引:2
作者
Frade, Joana Vieitez [1 ]
Filipe, Paulo [1 ,2 ,3 ]
机构
[1] North Lisbon Univ Hosp Ctr, Dermatol & Venereol Dept, Lisbon, Portugal
[2] Univ Lisbon, Inst Mol Med, Dermatol Invest Unit, Fac Med, Lisbon, Portugal
[3] Univ Lisbon, Fac Med, Univ Dept Dermatol, Lisbon, Portugal
关键词
cutaneous lupus erythematosus; pregnancy; systemic lupus erythematosus; treatment; TOPICAL CORTICOSTEROIDS; MATERNAL EXPOSURE; DOUBLE-BLIND; OUTCOMES; HYDROXYCHLOROQUINE; RECOMMENDATIONS; TACROLIMUS; DISEASE; SAFETY; WOMEN;
D O I
10.1111/dth.15486
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Lupus erythematosus is an autoimmune disease that often affects the skin. Cutaneous manifestations are generally subdivided into different subtypes, including acute, subacute, and chronic courses. Management of lupus erythematosus cutaneous manifestations during pregnancy remains a clinical challenge until nowadays. To date, no recommendations have been published specifically for the treatment of this condition in pregnant women, so therapeutic strategies are mainly based on recommendations for general population and other rheumatologic and dermatologic diseases during pregnancy. This challenge is compounded by a lack of evidence-based studies, as clinical trials in pregnant women are considered unethical in many circumstances, so data are often extrapolated from low-evidence sources. The aim of this article consists in review currently evidence of treatment of lupus erythematosus cutaneous lesion in pregnant women.
引用
收藏
页数:8
相关论文
共 44 条
  • [1] EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
    Andreoli, L.
    Bertsias, G. K.
    Agmon-Levin, N.
    Brown, S.
    Cervera, R.
    Costedoat-Chalumeau, N.
    Doria, A.
    Fischer-Betz, R.
    Forger, F.
    Moraes-Fontes, M. F.
    Khamashta, M.
    King, J.
    Lojacono, A.
    Marchiori, F.
    Meroni, P. L.
    Mosca, M.
    Motta, M.
    Ostensen, M.
    Pamfil, C.
    Raio, L.
    Schneider, M.
    Svenungsson, E.
    Tektonidou, M.
    Yavuz, S.
    Boumpas, D.
    Tincani, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (03) : 476 - 485
  • [2] Aringer M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI [10.1002/art.40930, 10.1136/annrheumdis-2018-214819]
  • [3] Blake Stephanie Clare, 2019, Int J Womens Dermatol, V5, P320, DOI 10.1016/j.ijwd.2019.07.004
  • [4] Bozzo P, 2011, CAN FAM PHYSICIAN, V57, P665
  • [5] Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy
    Braunstein, Inbal
    Werth, Victoria
    [J]. DERMATOLOGIC THERAPY, 2013, 26 (04) : 354 - 363
  • [6] Treatment of Cutaneous Lupus
    Chang, Aileen Y.
    Werth, Victoria P.
    [J]. CURRENT RHEUMATOLOGY REPORTS, 2011, 13 (04) : 300 - 307
  • [7] Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review
    Chasset, Francois
    Frances, Camille
    [J]. DRUGS, 2019, 79 (11) : 1199 - 1215
  • [8] Safety of Topical Corticosteroids in Pregnancy
    Chi, Ching-Chi
    Wang, Shu-Hui
    Kirtschig, Gudula
    [J]. JAMA DERMATOLOGY, 2016, 152 (08) : 934 - 935
  • [9] Pregnancy Outcomes After Maternal Exposure to Topical Corticosteroids: A UK Population-Based Cohort Study
    Chi, Ching-Chi
    Wang, Shu-Hui
    Mayon-White, Richard
    Wojnarowska, Fenella
    [J]. JAMA DERMATOLOGY, 2013, 149 (11) : 1274 - 1280
  • [10] Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy
    Edwards, MJ
    Agho, K
    Attia, J
    Diaz, P
    Hayes, T
    Illingworth, A
    Roddick, LG
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2003, 120A (04): : 459 - 463